FMP

FMP

Enter

APM - Aptorum Group Limite...

photo-url-https://images.financialmodelingprep.com/symbol/APM.png

Aptorum Group Limited

APM

NASDAQ

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

1.12 USD

0.01 (0.893%)

Operating Data

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

535.17k

911.51k

1.54M

1.3M

431.38k

492.64k

562.61k

642.51k

733.76k

837.97k

Revenue %

-

70.32

69.15

-15.95

-66.71

14.2

14.2

14.2

14.2

Ebitda

-15.12M

6.5M

-19.29M

-17.59M

-9.6M

-295.59k

-337.56k

-385.51k

-440.26k

-502.78k

Ebitda %

-2.82k

712.93

-1.25k

-1.36k

-2.23k

-60

-60

-60

-60

Ebit

-16.42M

5.16M

-20.48M

-18.8M

-10.72M

-295.59k

-337.56k

-385.51k

-440.26k

-502.78k

Ebit %

-3.07k

566.51

-1.33k

-1.45k

-2.49k

-60

-60

-60

-60

Depreciation

1.3M

1.33M

1.19M

1.21M

1.13M

463.61k

529.45k

604.64k

690.51k

788.58k

Depreciation %

242.84

146.42

77.35

93.18

260.85

94.11

94.11

94.11

94.11

EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep